← FDA Drug Approvals (Drugs@FDA)
DIFLUPREDNATE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: MYLAN LABS LTD · Approved 2025-03-20
Drug application
- FDA Application #
ANDA212566- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- DIFLUPREDNATE
- Generic name
- DIFLUPREDNATE
- Active ingredients
- DIFLUPREDNATE
- Dosage form
- EMULSION
- Route
- OPHTHALMIC
- Marketing status
- Prescription
- Sponsor
- MYLAN LABS LTD
- Manufacturer
- Mylan Pharmaceuticals Inc.
- First approval
- 2025-03-20
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown